P3.12E.03 Anti-Tumor Efficacy of HRS-4642 and its Potential Combination with Proteasome Inhibition in KRAS G12D-Mutant Cancer
Back to course
Pdf Summary
Asset Subtitle
Shengxiang Ren
Meta Tag
Speaker Shengxiang Ren
Topic Metastatic NSCLC – Targeted Therapy
Keywords
HRS-4642
KRAS G12D-mutant
anti-tumor efficacy
non-small cell lung cancer
NSCLC
CRISPR screenings
proteasome inhibitor
carfilzomib
immune activation
combination therapy
Powered By